检索结果-南通市图书馆

Fine genetic mapping of the chromosome 11q23.3 region in a Han chinese population:insights into the apolipoprotein genes underlying the blood lipid-lipoprotein variances

在线全文

学校读者我要写书评

暂无评论

Journal of Genetics and genomics 2020年第12期47卷 756-769页

作者： weihua Shou Chenhui Zhang jinxiu shi Hong Wu wei Huan Department of Genetics Shanghai-MOST Key Laboratory of Health and Disease GenomicsChinese National Human Genome Center at Shanghai and Shanghai Academy of Science and TechnologyShanghai 200025China Department of Cardiology Changhai HospitalThe Second Military Medical UniversityShanghai 200433China

The unusual chromosome 11q23.3 harboring the apolipoprotein(APO)gene cluster has been well documented for its essential roles in plasma lipid-related traits and atherosclerotic cardiovascular ***,its genetic architecture and the potential biological mechanisms underlying complex phenotypes have not been well *** conducted a study for this target region in a Han chinese population through a stepwise forward framework based on massive parallel sequencing,association analyses,genetic fine mapping,and functional *** present study identified new meaningful genetic associations that were not simply determined by statistical *** addition to the APOA5 gene,we found robust evidence of the genetic commitments of APOC3 and APOA1 to blood *** variants with high confidence were prioritized along with the potential biological mechanism interpretations in the wake of adaptive fine-mapping ***2849174 in the APOC3 enhancer was discovered with an unrivaled posterior probability of causality for triglyceride levels and could mediate APOC3 expression through enhancer activity modulated by a combination of histone modifications and transcription factor ***,multiple lines of evidence converged in favor of rs3741297 as a causal variant influencing high-density lipoprotein *** findings provided novel insights into this genomic locus in the chinese population.

关键词： APO gene cluster Blood lipids Coronary artery disease Genetic associations Progressive analyses for prioritizing Causal genetic factors

Trajectories of oxygen saturation within 6–72 hours after birth in neonates at moderate altitude:a prospective longitudinal cohort study

在线全文

学校读者我要写书评

暂无评论

World Journal of Pediatrics 2023年第9期19卷 894-901页

作者： Qu‑Ming Zhao Hong‑Yan Chen shi‑Xiu Li wei‑Li Yan Xiao‑Jing Hu Guo‑ying huang Children’s Hospital of Fudan University National Children’s Medical Center399 Wan Yuan RoadShanghai 201102China shanghai key laboratory of Birth Defects 399 Wan Yuan RoadShanghai 201102China Luchun County People’s Hospital LuchunChina Research Unit of Early Intervention of Genetically Related Childhood Cardiovascular diseases(2018RU002) Chinese Academy of Medical SciencesShanghaiChina

Trajectories of pulse oxygen saturation(SpO_(2))within the first few days after birth are important to inform the strategy for identifying asymptomatic hypoxemic disease but remain poorly substantiated at higher *** We performed a longitudinal cohort study with consecutive neonates at a local hospital in Luchun County,china,at an altitude of 1650 m between January and July *** repeatedly measured the pre-and post-ductal SpO_(2)values at 6,12,18,24,36,48,and 72 hours after birth for neonates without oxygen *** neonates underwent echocardiography and were followed up to 42 days after *** included neonates without hypoxemic diseases to characterize the trajectories of SpO_(2)over time using a linear mixed *** considered the 2.5th percentile as the reference value to define hypoxemic *** A total of 1061 neonates were ***-five had non-cardiac hypoxemic diseases,with 84%(21/25)presenting with abnormal SpO_(2)within 24 *** had tetralogy of Fallot identified by *** the 1035 asymptomatic neonates,SpO_(2)values declined from 6 hours after birth,reached a nadir at 48 hours,and tended to level off thereafter,with identical patterns for both pre-and post-ductal SpO_(2).The reference percentile was 92%for both pre-and post-ductal SpO_(2)and was time *** A decline within 48 hours features SpO_(2)trajectories within the first 72 hours at moderate *** findings suggest that earlier screening may favorably achieve a benefit–risk balance in identifying asymptomatic hypoxemic diseases in this population.

关键词： Critical congenital heart disease Hypoxemic disease Pulse oximetry screening Pulse oxygen saturation

Treatment and surveillance for non-muscle-invasive bladder cancer:a clinical practice guideline(2021 edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2023年第2期10卷 141-161页

作者： ying-Hui Jin Xian-Tao Zeng Tong-Zu Liu Zhi-Ming Bai Zhong-Ling Dou De-Gang Ding Zhi-Lu Fan Ping Han Yi-Ran huang Xing huang Ming Li Xiao-Dong Li Yi-Ning Li Xu-Hui Li Chao-Zhao Liang Jiu-Min Liu Hong-Shun Ma Juan Qi Jia-Qi shi Jian wang De-Lin wang Zhi-Ping wang Yun-Yun wang Yong-Bo wang Qiang wei Hai-Bo Xia Jin-Chun Xing Si-Yu Yan Xue-Pei Zhang Guo-You Zheng Nian-Zeng Xing Da-Lin He Xing-Huan wang on behalf of the chinese Urological Doctor Association(CUDA),Urological Association of chinese Research Hospital Association(CRHA-UA),Uro-health Promotive Association of china International Exchange,Promotive Association for Medical,health Care(CPAM-UHPA) center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Urology Haikou People’s HospitalHaikou Afliated Hospital of Central South University Xiangya School of MedicineHaikou 570208China Department of Urology the First Afliated Hospital and College of Clinical MedicineHenan University of Science and TechnologyLuoyang 450052HenanChina Department of Urology Henan Provincial People’s Hospi-talZhengzhou University People’s HospitalZhengzhou 450003China Department of Urology the Second Hospital of Dalian Medical UniversityDalian 116023LiaoningChina Department of Urology Institute of UrologyWest China HospitalSichuan UniversityChengdu 610041China Department of Urology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200120China Department of Urology the People’s Hos-pital of Xinjiang Uygur Autonomous RegionUrumqi 830002China Depart-ment of Urology Huaihe Hospital of Henan UniversityKaifeng 475000HenanChina Institutes of Evidence-Based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Urology the Second Afliated Hospital and Second Clinical Medical College of Fujian Medical UniversityQuanzhou 362000FujianChina Department of Urol-ogy the First Afliated Hospital of Anhui Medical UniversityHefei 230022China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou 510080China Department of Urology Tianjin First Central HospitalTianjin 300190China Department of Urology Xinhua HospitalSchool of MedicineShanghai Jiao Tong University School of MedicineShanghai 200092China Department of Urology Afliated Hospital of Guizhou Medical UniversityGuiyang 550004China Department of Urology Qinghai University Afliated HospitalXining 810012China Department of Urology the First Afliated Hospital of Chongqing Medical Univ

Non-muscle invasive bladder cancer(NMIBC)is a major type of bladder cancer with a high incidence worldwide,resulting in a great disease *** and surveillance are the most important part of NIMBC *** 2018,we issued“Treatment and surveillance for non-muscle-invasive bladder cancer in china:an evidencebased clinical practice guideline”.Since then,various studies on the treatment and surveillance of NMIBC have been *** is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in *** a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore *** formed a working group of clinical experts and *** questionnaire investigation of clinicians including primary medical institutions,24 clinically concerned issues,involving transurethral resection of bladder tumor(TURBT),intravesical chemotherapy and intravesical immunotherapy of NMIBC,and follow-up and surveillance of the NMIBC patients,were determined for this *** and recommendations on the management of NMIBC in databases,guideline development professional societies and monographs were referred to,and the European Association of Urology was used to assess the certainty of generated ***,we issued 29 statements,among which 22 were strong recommendations,and 7 were weak *** recommendations cover the topics of TURBT,postoperative chemotherapy after TURBT,Bacillus Calmette–Guérin(BCG)immunotherapy after TURBT,combination treatment of BCG and chemotherapy after TURBT,treatment of carcinoma in situ,radical cystectomy,treatment of NMIBC recurrence,and follow-up and *** hope these recommendations can help promote the treatment and surveillance of NMIBC in china,especially for the primary medical institutions.

关键词： Non-muscle invasive bladder cancer Bladder cancer Transurethral resection of bladder tumor Treatment Surveillance Guideline

Efficacy and safety of a sequential treatment with clearing heat and eliminating phlegm and tonifying Qi and activating blood circulation in treating acute ischemic stroke: study protocol for a randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Traditional chinese Medicine 2022年第4期42卷 604-610页

作者： ZHOU Ziyi WAN Can ZHAO Yuanqi LIU Xiangzhe GAO ying AN Hongwei LI Lejun ZHANG Huili YU Xiaofei ZHANG Xinchun wang Huijuan shi Qing wei Chunhua CHEN Jie huang Wenguo CHEN Junbin GAO ying HU Mingzhe CAI Yefeng Department of Neurology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120China the Second Clinical College of Guangzhou University of chinese Medicine Guangzhou 510120China Department of Neurology The First Affiliated Hospital of Henan University of Traditional Chinese MedicineZhengzhou 450000China Department of Neurology Shenyang Second Hospital of Traditional Chinese MedicineShenyang 110100China Department of Neurology Liuzhou Traditional Chinese Medical HospitalLiuzhou 545001China Department of Neurology Wuxi Traditional Chinese Medicine HospitalWuxi 214071China Department of Neurology Qinhuangdao City Hospital of Traditional Chinese MedicineQinhuangdao 066000China Department of Neurology Shanghai Shuguang HospitalShanghai 200120China Department of Neurology the Second Hospital of Hebei Medical UniversityShijiazhuang 050000China Department of Neurology Jiangmen Wuyi Hospital of Traditional Chinese MedicineJiangmen 529000China Department of Neurology Nanshi Hospital Affiliated to Henan UniversityNanyang 473065China Department of Neurology Shanxi Province Hospital of Traditional Chinese MedicineXi'an 710003China Department of Neurology Maoming Hospital of Traditional Chinese MedicineMaoming 525000China Department of Neurology the Northern Guangdong People's HospitalShaoguan 512025China Department of Neurology and Stroke center Dongzhimen Hospital affiliated to Beijing University of Chinese MedicineBeijing 100700China

OBJECTIVE:To investigate the short-term efficacy and safety outcomes following a sequential treatment with clearing heat and eliminating phlegm(CHEP)formula and tonifying Qi and activating blood circulation(TQABC)formula in patients with acute ischemic stroke(AIS)within a 72 h time ***:In this randomized,multicenter,doubleblinded,placebo-controlled trial,500 participants will be randomly assigned in a ratio of 1∶1 to the CHEP+TQABC group or control *** addition to guidelinebased standard medical care,participants in the treatment group will receive the CHEP formula for the first 5 consecutive days followed by the TQABC formula for another 10 consecutive days,while those in the control group will receive CHEP formula placebo and TQABC formula placebo *** primary outcome measure will be the comparison of the change in the national Institutes of health Stroke Scale score from baseline to 15 days after *** secondary outcome measures will include the scores on the modified Rankin Scale,Barthel Index,Patient-Reported Outcomes,TCM symptom pattern(Zheng-hou)evaluation Scale,and the incidence of in-hospital *** assessment will include the physical examination,laboratory detection,any adverse events or serious adverse events,and the proportion of any complications during ***:The results of this study will provide objective and scientific data with which to assess the efficacy and safety of a sequential treatment based on“integrating disease and symptom pattern”for patients with AIS.

关键词： stroke clearing heat and eliminating phlegm tonifying Qi and activating blood circulation randomized controlled trial clinical protocols

Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第21期27卷 2895-2909页

作者： Deng Han Yuan-Liang Li Zhi-wei Zhou Fei Yin Jie Chen Fang Liu Yan-Fen shi wei wang Yu Zhang Xian-Jun Yu Jian-Ming Xu Run-Xiang Yang Chao Tian Jie Luo huang-ying Tan Department of Integrative Oncology China-Japan Friendship HospitalBeijing 100029China Department of Gastric and Pancreatic Surgery Sun Yat-Sen University Cancer CenterGuangzhou 510060Guangdong ProvinceChina Department of Gastroenterology Fourth Hospital of Hebei Medical UniversityShijiazhuang 050000Hebei ProvinceChina Department of Gastroenterology The First Affiliated Hospital Sun Yat-Sen UniversityGuangzhou 510080Guangdong ProvinceChina Department of Gastroenterology China-Japan Friendship HospitalBeijing 100029China Department of Pathology China-Japan Friendship HospitalBeijing 100029China Department of Pancreatic Surgery Fudan University Shanghai Cancer CenterShanghai 200032China Department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032China Pancreatic Cancer Institute Fudan UniversityShanghai 200032China shanghai Pancreatic Cancer Institute Shanghai 200032China Department of Gastrointestinal Oncology Affiliated Hospital Cancer CenterAcademy of Military Medical SciencesBeijing 100071China Second Department of Internal Medicine Yunnan Tumor HospitalKunming 650118Yunnan ProvinceChina

BACKGROUND Poorly differentiated gastric neuroendocrine neoplasms(PDGNENs)include gastric neuroendocrine carcinoma(NEC)and mixed adenoneuroendocrine carcinoma,which are highly malignant and rare tumors,and their incidence has increased over the past few ***,the clinicopathological features and outcomes of patients with PDGNENs have not been completely *** To investigate the clinicopathological characteristics and prognostic factors of patients with *** The data from seven centers in china from March 2007 to November 2019 were analyzed *** Among the 232 patients with PDGNENs,191(82.3%)were male,with an average age of 62.83±9.11 *** hundred and thirteen(49.34%)of 229 patients had a stage III disease and 86(37.55%)had stage IV ***(1.58%)of 190 patients had no clinical symptoms,while 187(98.42%)patients presented clinical *** tumors were mainly(89.17%)solitary and located in the upper third of the stomach(cardia and fundus of stomach:115/215,53.49%).most lesions were ulcers(157/232,67.67%),with an average diameter of 4.66±2.77 *** terms of tumor invasion,the majority of tumors invaded the serosa(116/198,58.58%).The median survival time of the 232 patients was 13.50 mo(7,31 mo),and the overall 1-year,3-year,and 5-year survival rates were 49%,19%,and 5%,*** to univariate analysis,tumor number,tumor diameter,gastric invasion status,American Joint Committee on Cancer(AJCC)stage,and distant metastasis status were prognostic factors for patients with *** analysis showed that tumor number,tumor diameter,AJCC stage,and distant metastasis status were independent prognostic factors for patients with *** The overall prognosis of patients with PDGNENs is *** outcomes of patients with a tumor diameter>5 cm,multiple tumors,and stage IV tumors are worse than those of other patients.

关键词： Poorly differentiated gastric neuroendocrine neoplasms Clinicopathological characteristics Prognosis Distant metastasis Tumor diameter

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2022年第12期42卷 1314-1330页

作者： Yuankai shi Lin Wu Xinmin Yu Puyuan Xing Yan wang Jianying Zhou Airong wang Jianhua shi Yi Hu Ziping wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli wang Feng Ye Xingya Li Junye wang Mengzhao wang Yunpeng Liu Yanqiu Zhao ying Yuan Jifeng Feng Zhendong Chen Jindong shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen wei Li Hongrui Niu Wenwei Hu Lijun wang Jianan huang Yang Zhang ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi wang Luyao Sun Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingP.R.China Department II of Thoracic Medicine Hunan Cancer HospitalChangshaHunanP.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of Respiratory diseases The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouZhejiangP.R.China The Third Department of Chemotherapy Weihai Municipal HospitalWeihaiShandongP.R.China Department of Medical Oncology Linyi Cancer HospitalLinyiShandongP.R.China Oncology Department General Hospital of Chinese People’s Liberation ArmyBeijingP.R.China Department of Chest Medicine Beijing Cancer HospitalBeijingP.R.China Department of Oncology Beijing Chao-Yang HospitalCapital Medical UniversityBeijingP.R.China Department of Medical Oncology Sir Run Run Shaw HospitalZhejiang UniversityHangzhouZhejiangP.R.China Department of Medical Oncology Xuzhou Central HospitalXuzhou Medical UniversityXuzhouJiangsuP.R.China Department of Medical Oncology Shanghai Pulmonary HospitalTongji UniversityShanghaiP.R.China Department of Lung Cancer Tianjin Medical University Cancer Institute and HospitalTianjinP.R.China Department of Medical Oncology Cancer HospitalThe First Affiliated Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityThe Third Clinical Medical CollegeFujian Medical UniversityXiamenFujianP.R.China Department of Medical Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenanP.R.China Department of Oncology Affiliated Hospital of Jining Medical UniversityJiningShandongP.R.China Department of Respiratory and Critical Care Medicine Peking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijingP.R.China Department of Medical Oncology Key L

Background:Treatment options for chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are *** study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic ***:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based *** were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance *** primary endpoint was overall survival(OS)in the full analysis set(FAS).Secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and ***:Between August 25,2017,and November 7,2018,290 patients were *** FAS,10 patients fromthe docetaxel armwere *** OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel *** median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel *** biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatme

关键词： Non-small cell lung cancer Carcinoma squamous cell Sintilimab Immunotherapy Survival Randomized controlled trial

Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Journal of Natural Medicines 2021年第6期19卷 473-480页

作者： wei Wen-Long WU shi-Fei LI Hao-Jv LI Zhen-wei QU Hua YAO Chang-Liang ZHANG Jian-Qing LI Jia-Yuan WU Wan-ying GUO De-An shanghai Research center for Modernization of Traditional chinese Medicine National Engineering Laboratory for TCM Standardization TechnologyShanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China

Huashi Baidu prescription(HSBDF),recommended in the Guideline for the Diagnosis and Treatment of Novel Coronavirus(2019-nCoV)Pneumonia(On Trials,the Seventh Edition),was clinically used to treat severe corona virus disease 2019(COVID-19)with cough,blood-stained sputum,inhibited defecation,red tongue *** study was aimed to elucidate and profile the knowledge on its chemical constituents and the potential anti-inflammatory effect in *** the study,the chemical constituents in extract of HSBDF were characterized by UPLC-Q-TOF/MS in both negative and positive modes,and the pro-inﬂammatory cytokines were measured by enzyme-linked immunosorbent assays(ELISA)to determine the effects of HSBDF in lipopolysaccharide(LPS)-stimulated RAW264.7 *** results showed that a total of 217 chemical constituents were tentativedly characterized in ***,HSBDF could alleviate the expression levels of IL-6 and TNF-αin the cell models,indicating that the antiviral effects of HSBDF might be associated with regulation of the inflammatory cytokines production in RAW264.7 *** hope that the results could be served as the basic data for further study of HSBDF on anti-COVID-19 effect.

关键词： Huashi Baidu prescription Corona virus disease 2019 Characterization of chemical constituents ELISA

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia(2021 Edition)

在线全文

学校读者我要写书评

暂无评论

Military Medical Research 2022年第5期9卷 515-533页

作者： Xian-Tao Zeng ying-Hui Jin Tong-Zu Liu Fang-Ming Chen De-Gang Ding Meng Fu Xin-Quan Gu Bang-Min Han Xing huang Zhi Hou Wan-Li Hu Xin-Li Kang Gong-Hui Li Jian-Xing Li Pei-Jun Li Chao-Zhao Liang Xiu-Heng Liu Zhi-Yu Liu Chun-Xiao Liu Jiu-Min Liu Guang-Heng Luo Yi Luo wei-Jun Qin Jian-Hong Qiu Jian-Xin Qiu Xue-Jun Shang Ben-Kang shi Fa Sun Guo-Xiang Tian Ye Tian Feng wang Feng wang Yin-Huai wang Yu-Jie wang Zhi-Ping wang Zhong wang Qiang wei Min-Hui Xiao Wan-Hai Xu Fa-Xian Yi Chao-Yang Zhu Qian-Yuan Zhuang Li-Qun Zhou Xiao-Feng Zou Nian-Zeng Xing Da-Lin He Xing-Huan wang 无 Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan430071China center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan430071China Department of Urology Tianjin Third Central Hospital Affiliated To Nankai UniversityTianjin300170China Department of Urology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China Department of Urology Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China Department of Urology China-Japan Union Hospital of Jilin UniversityChangchun130033China Department of Urology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai200080China Department of Urology Qinghai University Affiliated HospitalXi’ning810012China Department of Urology People’s Hospital of Hainan ProvinceHainan Affiliated Hospital of Hainan Medical University HaikouHaikou570311China Department of Urology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou310016China Department of Urology General Hospital of Ningxia Medical UniversityYinchuan750003China Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefei230022China Department of Urology Renmin Hospital of Wuhan UniversityWuhan430060China Department of Urology The Second Hospital of Dalian Medical UniversityDalian116023LiaoningChina Department of Urology Zhujiang Hospital of Southern Medical UniversityGuangzhou510282China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou510080China Department of Urology Surgery Guizhou Province People’s HospitalGuiyang550002China Department of Urology Xijing Hospital of Air Force Military Medical UniversityXi’an710032China Department of Urology The 980St Hospital of the PLA Joint Logistics Support Force(Bethune International Peace Hospital of PLA)Shijiazhuang050082China Department of Urology

Benign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different

关键词： Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia Recommendation Treatment Guideline

Defects and asymmetries in the visual pathway of non-human primates with natural strabismus and amblyopia

在线全文

学校读者我要写书评

暂无评论

Zoological Research 2023年第1期44卷 153-168页

作者： Feng Liu Zhong-Hao wang Wanjing huang ying Xu Xuan Sang Ruifeng Liu Zhou-Yue Li Ya-Lan Bi Lei Tang Jing-Yi Peng Jia-Ru wei Zhi-Chao Miao Jian-Hua Yan Sheng Liu State key laboratory of Ophthalmology Zhongshan Ophthalmic CenterSun Yat-Sen UniversityGuangdong Provincial Key Laboratory of Ophthalmology and Visual ScienceGuangzhouGuangdong 510060China Guangdong-Hongkong-Macao Institute of CNS Regeneration Jinan UniversityGuangzhouGuangdong 510632China European Molecular Biology laboratory European Bioinformatics Institute(EMBL-EBI)Wellcome Genome CampusCambridge CB101SDUK Translational Research Institute of Brain and Brain-Like Intelligence and Department of Anesthesiology Shanghai Fourth People’s Hospital Affiliated to Tongji University School of MedicineShanghai 200081China Guangdong Province key laboratory of Brain Function and disease GuangzhouGuangdong 510080China

Strabismus and amblyopia are common ophthalmologic developmental diseases caused by abnormal visual experiences. However, the underlying pathogenesis and visual defects are still not fully understood. most studies have used experimental interference to establish diseaseassociated animal models, while ignoring the natural pathophysiological mechanisms. This study was designed to investigate whether natural strabismus and amblyopia are associated with abnormal neurological defects. We screened one natural strabismic monkey(Macaca fascicularis) and one natural amblyopic monkey from hundreds of monkeys, and retrospectively analyzed one human strabismus case. Neuroimaging, behavioral,neurophysiological, neurostructural, and genovariation features were systematically evaluated using magnetic resonance imaging(MRI), behavioral tasks, flash visual evoked potentials(FVEP),electroretinogram(ERG), optical coherence tomography(OCT), and whole-genome sequencing(WGS), respectively. Results showed that the strabismic patient and natural strabismic and amblyopic monkeys exhibited similar abnormal asymmetries in brain structure, i.e., ipsilateral impaired right hemisphere. Visual behavior, visual function, retinal structure, and fundus of the monkeys were impaired. Aberrant asymmetry in binocular visual function and structure between the strabismic and amblyopic monkeys was closely related, with greater impairment of the left visual *** similar known mutant genes for strabismus and amblyopia were also identified. In conclusion,natural strabismus and amblyopia are accompanied by abnormal asymmetries of the visual system,especially visual neurophysiological and neurostructural defects. Our results suggest that future therapeutic and mechanistic studies should consider defects and asymmetries throughout the entire visual system.

关键词： Non-human primates Natural disease models Strabismic patients Strabismus Amblyopia